Taiho's S-1 misses Phase III endpoint

Taiho said S-1 plus cisplatin missed the primary endpoint of superior overall survival

Read the full 136 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE